$CARM
Carisma Therapeutics Inc

2018 Q4 Form 10-Q Financial Statement

#000148500318000120 Filed on November 09, 2018

View on sec.gov

Income Statement

Concept 2018 Q4 2018 Q3 2017 Q3
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.500M $3.830M $1.630M
YoY Change 75.88% 134.97% -74.41%
% of Gross Profit
Research & Development $4.670M $3.372M $3.619M
YoY Change 50.16% -6.83% 31.41%
% of Gross Profit
Depreciation & Amortization $50.00K $60.00K $50.00K
YoY Change -28.57% 20.0% 150.0%
% of Gross Profit
Operating Expenses $7.066M $14.40M $9.150M
YoY Change 7.17% 57.34% 0.33%
Operating Profit -$7.066M -$14.40M -$9.150M
YoY Change 7.17% 57.34% -146.85%
Interest Expense $0.00 $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $310.0K $382.0K $45.00K
YoY Change 520.0% 748.89% -204.65%
Pretax Income -$6.760M -$14.02M -$9.110M
YoY Change 3.21% 53.9% -146.74%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$6.757M -$14.02M -$9.105M
YoY Change 3.21% 53.93% -146.72%
Net Earnings / Revenue
Basic Earnings Per Share -$0.37
Diluted Earnings Per Share -$87.20K -$182.0K -$0.37
COMMON SHARES
Basic Shares Outstanding 77.46M shares 77.01M shares 24.69M shares
Diluted Shares Outstanding 24.69M shares

Balance Sheet

Concept 2018 Q4 2018 Q3 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $50.40M $57.90M $11.30M
YoY Change 242.86% 412.39% -63.19%
Cash & Equivalents $50.42M $57.86M $11.34M
Short-Term Investments
Other Short-Term Assets $1.300M $1.500M $800.0K
YoY Change 333.33% 87.5% -27.27%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $51.76M $59.39M $12.11M
YoY Change 245.48% 390.46% -61.94%
LONG-TERM ASSETS
Property, Plant & Equipment $321.0K $365.0K $585.0K
YoY Change -38.51% -37.61% -34.56%
Goodwill $13.06M $13.06M $13.06M
YoY Change 0.0% 0.0% 26.69%
Intangibles $46.40M $46.40M $46.40M
YoY Change 0.0% 0.0% 28.18%
Long-Term Investments
YoY Change
Other Assets $0.00 $61.00K $101.0K
YoY Change -100.0% -39.6% -71.14%
Total Long-Term Assets $59.81M $59.91M $60.16M
YoY Change -0.52% -0.42% 25.95%
TOTAL ASSETS
Total Short-Term Assets $51.76M $59.39M $12.11M
Total Long-Term Assets $59.81M $59.91M $60.16M
Total Assets $111.6M $119.3M $72.27M
YoY Change 48.56% 65.07% -9.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.367M $1.391M $1.366M
YoY Change 50.72% 1.83% -22.43%
Accrued Expenses $4.746M $5.170M $2.915M
YoY Change 24.47% 77.36% 16.97%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.113M $6.561M $4.404M
YoY Change 29.51% 48.98% -29.7%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $313.0K $311.0K $170.0K
YoY Change 45.58% 82.94%
Total Long-Term Liabilities $313.0K $311.0K $170.0K
YoY Change 45.58% 82.94%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.113M $6.561M $4.404M
Total Long-Term Liabilities $313.0K $311.0K $170.0K
Total Liabilities $67.35M $6.872M $4.574M
YoY Change 1264.82% 50.24% -26.99%
SHAREHOLDERS EQUITY
Retained Earnings -$186.0M -$179.3M -$145.8M
YoY Change 22.12% 22.98% 21.72%
Common Stock $77.00K $77.00K $25.00K
YoY Change 120.0% 208.0% 4.17%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $44.21M $50.40M $17.07M
YoY Change
Total Liabilities & Shareholders Equity $111.6M $119.3M $72.27M
YoY Change 48.56% 65.07% -9.19%

Cashflow Statement

Concept 2018 Q4 2018 Q3 2017 Q3
OPERATING ACTIVITIES
Net Income -$6.757M -$14.02M -$9.105M
YoY Change 3.21% 53.93% -146.72%
Depreciation, Depletion And Amortization $50.00K $60.00K $50.00K
YoY Change -28.57% 20.0% 150.0%
Cash From Operating Activities -$7.650M -$5.200M -$4.430M
YoY Change 110.74% 17.38% -120.41%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$10.00K $0.00 $10.00K
YoY Change -150.0% -100.0% -97.62%
Cash From Investing Activities -$10.00K $0.00 $10.00K
YoY Change -150.0% -100.0% -97.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 220.0K 90.00K 0.000
YoY Change -96.84% -100.0%
NET CHANGE
Cash From Operating Activities -7.650M -5.200M -4.430M
Cash From Investing Activities -10.00K 0.000 10.00K
Cash From Financing Activities 220.0K 90.00K 0.000
Net Change In Cash -7.440M -5.110M -4.420M
YoY Change -322.09% 15.61% -119.87%
FREE CASH FLOW
Cash From Operating Activities -$7.650M -$5.200M -$4.430M
Capital Expenditures $0.00
Free Cash Flow -$7.650M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2018-09-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001485003
CY2018Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
77456180 shares
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
Sesen Bio, Inc.
dei Entity Small Business
EntitySmallBusiness
true
dei Trading Symbol
TradingSymbol
SESN
CY2018Q1 ebio Class Of Warrant Or Right Expiration Period
ClassOfWarrantOrRightExpirationPeriod
P5Y
CY2018Q1 ebio Class Of Warrant Or Right Price Per Share
ClassOfWarrantOrRightPricePerShare
0.125
CY2018Q3 ebio Working Capital Net
WorkingCapitalNet
52800000 USD
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
907000 USD
CY2018Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1391000 USD
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3813000 USD
CY2018Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5170000 USD
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
463000 USD
CY2018Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
725000 USD
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
170330000 USD
CY2018Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
229585000 USD
CY2017Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2900906 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2900906 shares
CY2018Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13825984 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13825984 shares
CY2017Q4 us-gaap Assets
Assets
75097000 USD
CY2018Q3 us-gaap Assets
Assets
119295000 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
14981000 USD
CY2018Q3 us-gaap Assets Current
AssetsCurrent
59385000 USD
CY2017Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
3900000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
7600000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1169000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3055900 shares
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-425000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 USD
CY2018Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
7200000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
9900000 USD
CY2017Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
39600000 USD
CY2018Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
49500000 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14680000 USD
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57856000 USD
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25352000 USD
CY2017Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11348000 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14690000 USD
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57876000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14004000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
43186000 USD
CY2018Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.20
CY2018Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
8765496 shares
CY2018Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
7968128 shares
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34702565 shares
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
77088570 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34702565 shares
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
77088570 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
35000 USD
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
77000 USD
CY2017Q4 us-gaap Construction Payable Current
ConstructionPayableCurrent
2581000 USD
CY2018Q3 us-gaap Construction Payable Current
ConstructionPayableCurrent
3036000 USD
CY2018Q3 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0 USD
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0 USD
CY2017Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
12528000 USD
CY2018Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
12528000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
221000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
156000 USD
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.91
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.48
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
735000 USD
CY2018Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
623000 USD
CY2018Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2900000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
94000 USD
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
9000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
5000 USD
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
0 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
285000 USD
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1631000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6085000 USD
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3825000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8128000 USD
CY2017Q4 us-gaap Goodwill
Goodwill
13064000 USD
CY2018Q3 us-gaap Goodwill
Goodwill
13064000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-301000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
484000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
803000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1453000 USD
CY2017Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
46400000 USD
CY2018Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
46400000 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
75097000 USD
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
119295000 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4720000 USD
CY2018Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6561000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
52000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
58363000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
84000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14140000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15182000 USD
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-9105000 USD
us-gaap Net Income Loss
NetIncomeLoss
-22482000 USD
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-14015000 USD
us-gaap Net Income Loss
NetIncomeLoss
-26936000 USD
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
45000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
180000 USD
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
382000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
498000 USD
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
9150000 USD
us-gaap Operating Expenses
OperatingExpenses
23087000 USD
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
14397000 USD
us-gaap Operating Expenses
OperatingExpenses
27434000 USD
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9150000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-22662000 USD
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-14397000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-27434000 USD
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
34000 USD
CY2018Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
126000 USD
CY2018Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
61000 USD
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
120000 USD
CY2018Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
215000 USD
CY2018Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
311000 USD
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
45000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
180000 USD
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
382000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
498000 USD
us-gaap Payments For Restructuring
PaymentsForRestructuring
111000 USD
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2018Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
301000 USD
CY2018Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1529000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
58286000 USD
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
84000 USD
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
5000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
40000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
56000 USD
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
12000 USD
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
21000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
7300000 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
522000 USD
CY2018Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
365000 USD
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3619000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9402000 USD
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3372000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9406000 USD
CY2017Q4 us-gaap Restricted Cash
RestrictedCash
10000 USD
CY2018Q3 us-gaap Restricted Cash
RestrictedCash
20000 USD
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
10000 USD
CY2018Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
20000 USD
CY2017Q4 us-gaap Restructuring And Related Cost Expected Cost1
RestructuringAndRelatedCostExpectedCost1
100000 USD
CY2017Q4 us-gaap Restructuring Reserve
RestructuringReserve
111000 USD
CY2018Q3 us-gaap Restructuring Reserve
RestructuringReserve
0 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-152331000 USD
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-179267000 USD
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-179300000 USD
CY2018Q3 us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
0 USD
CY2017Q3 us-gaap Revenues
Revenues
0 USD
CY2018Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1.80
us-gaap Revenues
Revenues
425000 USD
CY2018Q3 us-gaap Revenues
Revenues
0 USD
CY2018Q3 us-gaap Revenues
Revenues
0 USD
us-gaap Revenues
Revenues
0 USD
CY2018Q1 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
9000000 USD
CY2018Q2 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
41900000 USD
us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
50900000 USD
CY2018Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
7968128 shares
CY2018Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
25555556 shares
CY2018Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1.13
us-gaap Severance Costs1
SeveranceCosts1
100000 USD
CY2017Q3 us-gaap Share Based Compensation
ShareBasedCompensation
253000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
819000 USD
CY2018Q3 us-gaap Share Based Compensation
ShareBasedCompensation
248000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
935000 USD
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1868379 shares
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.35
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1111941 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2695796 shares
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4568352 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.16
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.42
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.79
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.40
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.72
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
71403 shares
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
18034000 USD
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
50395000 USD
CY2017Q4 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
0 USD
CY2018Q3 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
660000 USD
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24691000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24663000 shares
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
77030000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
56526000 shares

Files In Submission

Name View Source Status
0001485003-18-000120-index-headers.html Edgar Link pending
0001485003-18-000120-index.html Edgar Link pending
0001485003-18-000120.txt Edgar Link pending
0001485003-18-000120-xbrl.zip Edgar Link pending
ebio-20180930.xml Edgar Link completed
ebio-20180930.xsd Edgar Link pending
ebio-20180930_cal.xml Edgar Link unprocessable
ebio-20180930_def.xml Edgar Link unprocessable
ebio-20180930_lab.xml Edgar Link unprocessable
ebio-20180930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sesn-093018x10q.htm Edgar Link pending
sesn-093018x311.htm Edgar Link pending
sesn-093018x312.htm Edgar Link pending
sesn-093018x321.htm Edgar Link pending
sesnexhibit101micrometli.htm Edgar Link pending
sesnexhibit101micrometli001.jpg Edgar Link pending
sesnexhibit101micrometli002.jpg Edgar Link pending
sesnexhibit101micrometli003.jpg Edgar Link pending
sesnexhibit101micrometli004.jpg Edgar Link pending
sesnexhibit101micrometli005.jpg Edgar Link pending
sesnexhibit101micrometli006.jpg Edgar Link pending
sesnexhibit101micrometli007.jpg Edgar Link pending
sesnexhibit101micrometli008.jpg Edgar Link pending
sesnexhibit101micrometli009.jpg Edgar Link pending
sesnexhibit101micrometli010.jpg Edgar Link pending
sesnexhibit101micrometli011.jpg Edgar Link pending
sesnexhibit101micrometli012.jpg Edgar Link pending
sesnexhibit101micrometli013.jpg Edgar Link pending
sesnexhibit101micrometli014.jpg Edgar Link pending
sesnexhibit101micrometli015.jpg Edgar Link pending
sesnexhibit101micrometli016.jpg Edgar Link pending
sesnexhibit101micrometli017.jpg Edgar Link pending
sesnexhibit101micrometli018.jpg Edgar Link pending
sesnexhibit101micrometli019.jpg Edgar Link pending
sesnexhibit101micrometli020.jpg Edgar Link pending
sesnexhibit101micrometli021.jpg Edgar Link pending
sesnexhibit101micrometli022.jpg Edgar Link pending
sesnexhibit101micrometli023.jpg Edgar Link pending
sesnexhibit101micrometli024.jpg Edgar Link pending
sesnexhibit101micrometli025.jpg Edgar Link pending
sesnexhibit101micrometli026.jpg Edgar Link pending
sesnexhibit101micrometli027.jpg Edgar Link pending
sesnexhibit101micrometli028.jpg Edgar Link pending
sesnexhibit101micrometli029.jpg Edgar Link pending
sesnexhibit101micrometli030.jpg Edgar Link pending
sesnexhibit101micrometli031.jpg Edgar Link pending
sesnexhibit101micrometli032.jpg Edgar Link pending
sesnexhibit101micrometli033.jpg Edgar Link pending
sesnexhibit101micrometli034.jpg Edgar Link pending
sesnexhibit101micrometli035.jpg Edgar Link pending
sesnexhibit101micrometli036.jpg Edgar Link pending
sesnexhibit101micrometli037.jpg Edgar Link pending
sesnexhibit101micrometli038.jpg Edgar Link pending
sesnexhibit102xomanonexc.htm Edgar Link pending
sesnexhibit102xomanonexc001.jpg Edgar Link pending
sesnexhibit102xomanonexc002.jpg Edgar Link pending
sesnexhibit102xomanonexc003.jpg Edgar Link pending
sesnexhibit102xomanonexc004.jpg Edgar Link pending
sesnexhibit102xomanonexc005.jpg Edgar Link pending
sesnexhibit102xomanonexc006.jpg Edgar Link pending
sesnexhibit102xomanonexc007.jpg Edgar Link pending
sesnexhibit102xomanonexc008.jpg Edgar Link pending
sesnexhibit102xomanonexc009.jpg Edgar Link pending
sesnexhibit102xomanonexc010.jpg Edgar Link pending
sesnexhibit102xomanonexc011.jpg Edgar Link pending
sesnexhibit102xomanonexc012.jpg Edgar Link pending
sesnexhibit102xomanonexc013.jpg Edgar Link pending
sesnexhibit102xomanonexc014.jpg Edgar Link pending
sesnexhibit102xomanonexc015.jpg Edgar Link pending
Show.js Edgar Link pending